This speculative small-cap vaccine developer was a top stock in 2014. With its Ebola vaccine in the works, does it have enough to keep flying in 2015?
source CNBC
Novavax CEO Stanley Erck| Mad Money | CNBC
This speculative small-cap vaccine developer was a top stock in 2014. With its Ebola vaccine in the works, does it have enough to keep flying in 2015?
source CNBC
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More